Putting It in Perspective Using Medications for Chronic Weight Management. Donna H. Ryan, MD Pennington Biomedical Research Center

Size: px
Start display at page:

Download "Putting It in Perspective Using Medications for Chronic Weight Management. Donna H. Ryan, MD Pennington Biomedical Research Center"

Transcription

1

2 Putting It in Perspective Using Medications for Chronic Weight Management Donna H. Ryan, MD Pennington Biomedical Research Center

3 Why Use Medications? Medications help patients lose more weight when they are trying to diet. Medications can: reduce hunger, improve satisfaction with smaller meals, make patients resist tempting foods or foods they crave or, in the case of Xenical, help reinforce a low fat diet.

4 Why do we need drugs for weight loss? To help patients better adhere to their dietary plan, To help more patients achieve meaningful weight loss, To produce more weight loss so that health benefits will be greater, and To help patients sustain lost weight.

5 Why have medications gotten a bad rap? Older medications were not safe. They weren t studied properly! Short-term studies, few patients. We thought we could produce weight loss and the patient would be cured. The science of obesity was not understood. We thought patients just needed to be told to eat less and exercise more and try harder.

6 How are newer medications evaluated? FDA requires comparison of >2000 patients treated with medication and a similar number on placebo. They evaluate efficacy (average weight loss, percentage who can achieve 5% or more or 10% or more weight loss and improvement in risk factors). They evaluate safety adverse events recorded at every visit, effect on mood recorded at every visit, routing labs and labs of special interest. If the drug passes initial testing a large study (~10,000 people) is conducted testing the effect on heart attack and stroke.

7 When do patients need medications? Medications can help patients who need to lose weight to improve health; who are struggling to lose weight with lifestyle change; who don t have any contraindications to a particular medication; and who need help maintaining lost weight.

8 Some important facts about medications for chronic weight management There is no ideal medication. In the right patient, every medication can be a good medication. In the wrong patient, every medication can be a bad medication. Medications don t work in every patient. The medication profile must be matched to the patient profile. They don t work on their own!

9 Xenical or Alli -otc (orlistat)

10 Belviq (lorcaserin)

11 Qsymia (phentermine/topiramate SR)

12 Contrave (naltrexone SR/bupropion SR)

13 Saxenda (liraglutide 3.0 mg)

14 Thank you!

15 Navigating Medications: Choosing the Options Best for YOU! Christopher D. Still, DO, FACN, FACP

16 General Principles of Choosing Weight Loss Medications ALL medications will be most effective when used in conjunction with a reduced calorie meal plan and increased physical activity The more you can be accountable, (food and exercise logs, daily weights, frequent follow ups*,etc), the greater weight loss. Not every medication will work on every patient Need to have REALISTIC expectations I have lost 35 pounds and hit a plateau I ve developed a tolerance to my medication and it doesn t work anymore

17 Phentermine/Topiramate ER (Qsymia) May help migraine headaches or chronic pain Produced most weight loss of all medications approved Has been used with patients with depression Pregnancy fetal toxicity Glaucoma HYPERthyroidism Uncontrolled blood pressure Heart problems (arrhythmias, etc) Capsules taken daily Produces ~ 12% weight loss after 1 year

18 Lorcaserin (Belviq) Well tolerated; few side effects May help blood sugar control Should not increase blood pressure Caution with depression medications like fluoxetine (Prozac), paroxetine (Paxil), etc Tablet taken twice daily Produces ~7% weight loss after 1 year

19 Naltrexone SR/Bupropion SR (Contrave) Smoker Alcohol use Seizure disorder Uncontrolled blood pressure Opioid use oxycodone Tablets taken twice daily Produces ~ 9% weight loss at 1 year

20 Liraglutide 3.0 mg Diabetic Injected daily Produces ~ 9% weight loss ay 1 year History of pancreatitis Thyroid cancer Kidney probles

21 Odds of Reducing Body Weight by % Categories at 1 Year with Adjunctive Medication Among those who Complete Treatment* % % weight loss 10% weight loss *combined with lifestyle modification

22 Recap Do you have history of glaucoma? Qsymia and Contrave aren t the best choice for you Do you have kidney stones? Avoid Qsymia Do you or a family member have thyroid cancer? Saxsenda is not for you Do you take an SSRI for depression? Qysmia has been used in that patient population Do you need better blood sugar control? Saxsenda and Belviq would be your best option Do you have insurance coverage? NO? Contrave has special pricing

23 Understanding My Surgical Options Walter Medlin, MD, FACS

24 Indications for procedure BMI controversial, but still mostly used >27 with Diabetes, Asian, Indian, Native American >30 with any comorbidity (related problem) DO NOT ASSUME THAT you don t have any until evaluated with exam, labs, sleep study, endoscopy DO NOT ASSUME THAT BMI of 35 is medically required, but still many insurance limits (not Medicaid, few others) Self pay = your & MD call

25 Considerations, Tradeoffs Your tolerance for risk vs uncertainty Money yours or insurance? Diabetes Hiatal Hernia/GERD Weight requirement esp. for knee arthritis Pregnancy plans Mission/overseas work or extended life

26

27

28

29

30

31

32

33

34

35

36

37

38

39

ACHIEVING HEALTH: AGENDA: Achieving Health: A Look at Your Weight Management Options

ACHIEVING HEALTH: AGENDA: Achieving Health: A Look at Your Weight Management Options ACHIEVING HEALTH: A Look at Your Weight Management Options Achieving Health: A Look at Your Weight Management Options AGENDA: Achieving Health: A Look at Your Weight Management Options Topic 1 Behavior

More information

Anti-Obesity Agents Drug Class Prior Authorization Protocol

Anti-Obesity Agents Drug Class Prior Authorization Protocol Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review

More information

An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD

An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College

More information

WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?

WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein

More information

2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N

2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N Prior Authorization MERC CARE PLA Weight Reduction Medications (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and

More information

What is obesity? OBESITY. Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health.

What is obesity? OBESITY. Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health. OBESITY What is obesity? Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health. Obesity is most often measured by body mass index (BMI), which looks at

More information

Obesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH

Obesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy

More information

FDA approves Belviq to treat some overweight or obese adults

FDA approves Belviq to treat some overweight or obese adults FDA approves Belviq to treat some overweight or obese adults Silver Spring, MD, USA (June 27, 2012) - The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition

More information

Losing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise.

Losing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise. OBESITY Treatment Losing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise. If you ve tried on your own and still find that you

More information

Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine

Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy Shelby Sullivan University of Colorado School Of Medicine Disclosures Research Support / Grants R01DK094483-02 Klein/Mittendorfer

More information

Understanding Obesity: The Causes, Effects, and Treatment Options

Understanding Obesity: The Causes, Effects, and Treatment Options Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,

More information

WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association

WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association MEGAN N DUNLOP, PHARMD, CTTS CLINICAL PHARMACIST, UPMC COMMUNITY PROVIDER SERVICES LEARNING OBJECTIVES

More information

Where are We Now? Editor s Note: Who Qualifi es for Obesity Medications?

Where are We Now? Editor s Note: Who Qualifi es for Obesity Medications? Obesity Medications Where are We Now? by Christopher D. Still, DO, FACP, FACN, Nadia Boulghassoul-Pietrzykowska, MD, and Jennifer E. Franceschelli, DO Editor s Note: Please note that some of the medications

More information

MEDICAL MANAGEMENT 101

MEDICAL MANAGEMENT 101 MEDICAL MANAGEMENT 101 Christopher Still, DO, FACN, FACP Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research Institute Geisinger Health Care System Your Weight

More information

Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background

Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence

More information

The US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon

The US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women

More information

What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?

What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,

More information

Update on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018

Update on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018 Update on the Recent Advances in Obesity Management Benjamin O Donnell, MD Oct 5 th, 2018 Objectives Background Control of Energy Homeostasis Approach to Diet and Exercise Medications Recently Approved

More information

When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity

When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After

More information

Overview of Management of Obesity

Overview of Management of Obesity Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives

More information

Disclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014

Disclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014 Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity

More information

APhA March 2016 Annual Meeting Obesity Cases

APhA March 2016 Annual Meeting Obesity Cases APhA March 2016 Annual Meeting Obesity Cases Case #1 Pam is a 47 yo obese Caucasian woman; grade school teacher with a history of HTN, HoTR, and depression who presents for her annual physical. CC: I m

More information

Obesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%

Obesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10% Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women

More information

Cravings are one of the main reasons diets fail

Cravings are one of the main reasons diets fail ? Did you KNOW Cravings are one of the main reasons diets fail Help control your cravings and lose weight with CONTRAVE Actual patient. Results not typical. Across three studies, 46% of patients taking

More information

9 out of 10 people struggle with food cravings while dieting?

9 out of 10 people struggle with food cravings while dieting? CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical

More information

9 out of 10 people struggle with food cravings while dieting?

9 out of 10 people struggle with food cravings while dieting? CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical

More information

Managing Obesity as a Disease. Disclosure. Objectives

Managing Obesity as a Disease. Disclosure. Objectives Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity

More information

Without Background for printing as Pocket Reference

Without Background for printing as Pocket Reference Without Background for printing as Pocket Reference Diabetes Prevention Program 1 LOOK AHEAD 3 Multi-center trial in patients with impaired glucose tolerance Weight loss of 7% reduced the rate of progression

More information

Treating Obesity- NOT Just with Surgery

Treating Obesity- NOT Just with Surgery Treating Obesity- NOT Just with Surgery Identify obesity as a major health problem Define and describe causes of obesity with contributing factors. Discuss pertinent details to seeing an obese patient

More information

Management of obesity

Management of obesity From Behavior Modification through Pharmacotherapy to Surgery an Emphasis on the Team Approach Scott D. Isaacs, M.D., F.A.C.P., F.A.C.E. drisaacs@atlantaendocrine.com Understand the physician s role in

More information

Realistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013

Realistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013 Realistic Expectations: Drugs in the Treatment of Obesity Lora Cotton, D.O. January 20, 2013 Overview Approach FDA approved agents will be covered FDA approval guidelines Candidates Expectations Mechanisms,

More information

HEALTH TRANSITIONS CLINC: PART 1: Weight, Diet and Exercise History

HEALTH TRANSITIONS CLINC: PART 1: Weight, Diet and Exercise History HEALTH TRANSITIONS CLINC: Initial history questionnaire: Patient Name: DOB: Age: Sex Marital Status Occupation: Significant Other s Name PART 1: Weight, Diet and Exercise History Obesity history: Current

More information

The New Trend of Anti-Obesity Drug

The New Trend of Anti-Obesity Drug 2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity

More information

Faculty Disclosures. Vera Tarman, MD, Author:

Faculty Disclosures. Vera Tarman, MD, Author: Faculty Disclosures Vera Tarman, MD, Author: Food Junkies: The Truth About Food Addiction (book) Dangerous Liaisons: Comfort and Food (DVD) Biology of Addiction, Biology of Recovery (DVDs) Standard Treatments

More information

Insurance Questions for Medical Weight Loss

Insurance Questions for Medical Weight Loss Insurance Questions for Medical Weight Loss Verifying your insurance coverage and understanding the benefits specific to your own policy are extremely important steps in moving forward with your weight

More information

Understanding. Obesity. An educational resource provided by the Obesity Action Coalition

Understanding. Obesity. An educational resource provided by the Obesity Action Coalition Understanding Obesity An educational resource provided by the Obesity Action Coalition What is obesity? Obesity is a disease characterized by excessive body fat. People who are affected by obesity usually

More information

Weight History. General Patient Questions. Reason for Visit

Weight History. General Patient Questions. Reason for Visit General Patient Questions Age Reason for Visit General History Alcoholism Yes Hepatitis A Yes Anemia Yes Hepatitis B or C Yes Arthritis Yes Hernia Yes Asthma Yes High blood pressure Yes Bleeding tendency

More information

Clinical Policy: Weight Loss Reference Number: CP.CPA.197 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Weight Loss Reference Number: CP.CPA.197 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.197 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Special Report: The Miracle Supplement For Weight Loss And Optimum Health! By Joel Kaye, MA

Special Report: The Miracle Supplement For Weight Loss And Optimum Health! By Joel Kaye, MA Special Report: The Miracle Supplement For Weight Loss And Optimum Health! By Joel Kaye, MA www.rightbraindiet.com When one hears about water they would never think of it as the best weight loss supplement

More information

Name (Last Name, First Name): SSN #: Date of Birth: Age: Sex: M F Other. Address: Home phone: Work phone: Cell phone:

Name (Last Name, First Name): SSN #: Date of Birth: Age: Sex: M F Other. Address: Home phone: Work phone: Cell phone: SCREENING APPLICATION NOTE: THIS APPLICATION MUST BE COMPLETED BEFORE YOU CAN ENROLL IN THE NEW DIRECTION (ND) SYSTEM. PLEASE ANSWER EVERY QUESTION. PLEASE PRINT CLEARLY. Date: Name (Last Name, First Name):_

More information

Lorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, )

Lorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, ) (World Health organization, WHO) 1996 WHO (Body mass index, BMI)2427 kg/m 2 27 kg/m 2 25% 30%2013-2014 43.5%(48.9%38.3%) (AACE/ACE)2016 1 BMI 27 kg/m 2 BMI 35 kg/m 2 (The Food and Drug Administration,

More information

Overview of the Pharmacologic & Surgical Treatment for Obesity

Overview of the Pharmacologic & Surgical Treatment for Obesity Overview of the Pharmacologic & Surgical Treatment for Obesity Christopher D. Still, DO, FACN, FACP. FTOS Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research

More information

Let s s start with a case study.

Let s s start with a case study. Disclosure Dr. Ryan has received financial remuneration in 2015 from Amgen, Novo Nordisk, Janssen, Pfizer, Takeda, Vivus, Real Appeal, and Scientific Intake. Medicating the Patient with Obesity Clinical

More information

Obesity Management in Type 2 Diabetes

Obesity Management in Type 2 Diabetes Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe

More information

Clinical Policy: Weight Loss Reference Number: CP.CPA.200 Effective Date: Last Review Date: Line of Business: Commercial - HNCA

Clinical Policy: Weight Loss Reference Number: CP.CPA.200 Effective Date: Last Review Date: Line of Business: Commercial - HNCA Clinical Policy: Reference Number: CP.CPA.200 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important

More information

System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes

System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes Volume 30, Issue 2 November 2014 Afrezza (Technosphere Insulin Inhalation System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes Merly Suarez, PharmD Candidate D P PharmacodynamicsandPharmacokinetics

More information

Healthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40

Healthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40 A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 10, Issue 4 Winter 2015 T he American Medical Association, the World Health Organization, and the US Food and Drug Administration

More information

PHENTERMINE B12 LIPOTROPIC INJECTIONS

PHENTERMINE B12 LIPOTROPIC INJECTIONS PHENTERMINE B12 LIPOTROPIC INJECTIONS Phentermine B12 Lipotropic Injections Prescribed diet pills phentermine Phentermine diet pill withdrawal I need affordable phentermine in las vegas nevada How long

More information

PHENTERMINE INFORMATION SHEET

PHENTERMINE INFORMATION SHEET PHENTERMINE INFORMATION SHEET What is phentermine? Phentermine is a prescription weight loss medication. It is an appetite suppressant. Individuals taking phentermine lose weight because they are less

More information

Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA.

Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA. Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA Donna.Ryan@pbrc.edu National Summit on Health Disparities April 22, 2013 Disclosure Dr. Ryan has served as an advisor to Nutrisystem

More information

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast

More information

Clinical Nutrition Center

Clinical Nutrition Center Clinical Nutrition Center ETHAN LAZARUS, M.D. May 10 th, 2011 Address Block Dear Doctor: Thank you for all of your referrals to myself and the staff at Clinical Nutrition Center. There has been so much

More information

For Asian individuals the BMI numbers are 27.5 and 25 respectively These values are from the NICE guidelines of 2014

For Asian individuals the BMI numbers are 27.5 and 25 respectively These values are from the NICE guidelines of 2014 Ken Cathcart DO FACE We need to define several things to start the talk Obesity is defined medically as a BMI of greater than 30 or a BMI >27 with co-morbidities such as hypertension, type 2 DM, dyslipidemia,

More information

Modest weight loss of 5% to 10%

Modest weight loss of 5% to 10% These 4 cases illustrate how weight loss drugs including the 4 newest can be integrated into a treatment plan that includes diet, exercise, and behavior modification Katherine H. Saunders, MD; Alpana P.

More information

Monthly WellPATH Spotlight November 2016: Diabetes

Monthly WellPATH Spotlight November 2016: Diabetes Monthly WellPATH Spotlight November 2016: Diabetes DIABETES RISK FACTORS & SELF CARE TIPS Diabetes is a condition in which the body does not produce enough insulin or does not use the insulin produced

More information

Some college. Native American/ Other. 4-year degree 13% Grad work

Some college. Native American/ Other. 4-year degree 13% Grad work Access to Affordable Health Care Access to affordable care improves quality of life and health outcomes. Without affordable access to a doctor, residents are more likely to end up in expensive emergency

More information

OBESITY. Caroline Steinman DO

OBESITY. Caroline Steinman DO OBESITY Caroline Steinman DO No financial disclosures DISCLOSURES OUTLINE Statistics Medications Diets Exercise OBESITY STATISTICS IN INDIANA 65.9% overweight(12) 29.6% obese(12) 28.1% of adults report

More information

Treatment of Obesity: Diets, Drugs and Surgery

Treatment of Obesity: Diets, Drugs and Surgery Treatment of Obesity: Diets, Drugs and Surgery Disclosures None Michelle Guy, MD Professor Clinical Medicine University of California San Francisco Diplomate American Board of Obesity Medicine Objectives

More information

Approaches to Prevention and Management of Obesity Maj Sarah Kelly USAF

Approaches to Prevention and Management of Obesity Maj Sarah Kelly USAF CPE Information and Disclosures Approaches to Prevention and Management of Obesity Maj Sarah Kelly USAF Sarah Kelly declares that she owns stock in the following companies: Pfizer Medtronic The American

More information

Learning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD

Learning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms

More information

Using New Guidelines to Improve Best Practices in Obesity Management

Using New Guidelines to Improve Best Practices in Obesity Management Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Patient Packet. SSM Health Dean Medical Group Weight Management Services 1313 Fish Hatchery Road Madison, WI 53715

Patient Packet. SSM Health Dean Medical Group Weight Management Services 1313 Fish Hatchery Road Madison, WI 53715 Patient Packet Weight Management Services 1313 Fish Hatchery Road Madison, WI 53715 Welcome Thank you for your interest in SSM Health Weight Management Services. Please complete the enclosed questionnaire

More information

Approximately one third of the 15.7 million Americans who are estimated to have diabetes

Approximately one third of the 15.7 million Americans who are estimated to have diabetes Diabetes is a very serious illness and too many people are neglecting their condition. Approximately one third of the 15.7 million Americans who are estimated to have diabetes are unaware of their condition.

More information

Chapter 13 Weight Loss: A Healthy Lifestyle Side Effect

Chapter 13 Weight Loss: A Healthy Lifestyle Side Effect Brought to you by The Wellness Councils of America Chapter 13 Weight Loss: A Healthy Lifestyle Side Effect I ve been on a constant diet for the last two decades. I ve lost a total of 789 pounds. By all

More information

The prevalence of obesity in adults has doubled over the past 30 years

The prevalence of obesity in adults has doubled over the past 30 years Obesity in America: Facts and Fiction MICHAEL G. PERRI, PhD Professor, Clinical and Health Psychology Interim Dean, College of Public Health and Health Professions University of Florida Overview: Key Questions

More information

Am I at Risk for Type 2 Diabetes?

Am I at Risk for Type 2 Diabetes? Am I at Risk for Type Diabetes? Taking Steps to Lower Your Risk of Getting Diabetes On this page: What is type diabetes? Can type diabetes be prevented? What are the signs and symptoms of type diabetes?

More information

Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.

Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes. 1:55-2:4pm Medical Management of Obesity: Lifestyle, Medicine, and Surgery SPEAKER Osama Hamdy, MD, PhD, FACE Disclosures The following relationships exist related to this presentation: Osama Hamdy, MD,

More information

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as

More information

Faculty/Presenter Disclosure

Faculty/Presenter Disclosure Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning

More information

DOCTOR PRESCRIBED DIET PILLS PHENTERMINE 375 MG

DOCTOR PRESCRIBED DIET PILLS PHENTERMINE 375 MG DOCTOR PRESCRIBED DIET PILLS PHENTERMINE 375 MG Doctor Prescribed Diet Pills Phentermine 375 Mg Will taking phentermine affect birth control Phentermine work lose weight Is phentermine hcl safe after expiration

More information

Complete the Qsymia Healthcare Provider Training Program in 2 easy steps:

Complete the Qsymia Healthcare Provider Training Program in 2 easy steps: Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.

More information

AACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY

AACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY AACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY O B E S I T Y R E S O U R C E C E N T E R CO M M I T

More information

Making Changes: Cognitive Behavior Therapy for Binge Eating Disorder. Michele Laliberte, Ph.D., C.Psych.

Making Changes: Cognitive Behavior Therapy for Binge Eating Disorder. Michele Laliberte, Ph.D., C.Psych. Making Changes: Cognitive Behavior Therapy for Binge Eating Disorder Michele Laliberte, Ph.D., C.Psych. Making Changes Week 2 About Weight Outline of Session BED and Obesity Your health and body image

More information

Controversies in Obesity Management Public Meeting

Controversies in Obesity Management Public Meeting Controversies in Obesity Management Public Meeting July 14, 2015 1 Agenda Public Meeting Convened, Topic Overview 9:30 am Presentation of the Evidence and Economic Modeling, Q&A 9:35 10:40 am (Dr. Dan

More information

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,

More information

What s the Skinny?: An Update on Medications for Weight Management

What s the Skinny?: An Update on Medications for Weight Management What s the Skinny?: An Update on Medications for Weight Management Katura C. Bullock, PharmD, BCPS Associate Professor UNT System College of Pharmacy SESSION OBJECTIVES 1. Recognize the prevalence of obesity

More information

Reduce hunger and help control cravings with CONTRAVE

Reduce hunger and help control cravings with CONTRAVE Reduce hunger and help control cravings with CONTRAVE Understanding and identifying patients who are ready to start their weight-loss journey with CONTRAVE is key to helping them reach their weight-loss

More information

Management of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.

Management of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications. Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According

More information

Am I at Risk for Type 2 Diabetes?

Am I at Risk for Type 2 Diabetes? NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for Type 2 Diabetes? Taking Steps to Lower Your Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health

More information

Prediabetes 101. What is it and what can I do about it? Intermountainhealthcare.org/diabetes

Prediabetes 101. What is it and what can I do about it? Intermountainhealthcare.org/diabetes Prediabetes 101 What is it and what can I do about it? Patient Education Intermountainhealthcare.org/diabetes What do you already know about prediabetes? Fact or Fiction? There are often no symptoms of

More information

Update on Treating Obesity: A Multidisciplinary Approach. Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living

Update on Treating Obesity: A Multidisciplinary Approach. Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living Update on Treating Obesity: A Multidisciplinary Approach Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living Objectives 1. Define obesity as a disease 2. List the stepwise approach to obesity treatment

More information

pennsylvania DEPARTMENT OF HUMAN SERVICES

pennsylvania DEPARTMENT OF HUMAN SERVICES Testimony on Coverage of Anti-Obesity Drugs as a Compensable Service in the Medical Assistance Program Terri Cathers, Pharm. D. Director of Pharmacy Programs Office of Medical Assistance Programs House

More information

Behavioral Modification and Lorcaserin Second Study for Obesity Management

Behavioral Modification and Lorcaserin Second Study for Obesity Management BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallelgroup Study to Assess the Safety and Efficacy of Lorcaserin

More information

For Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity

For Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity Role of glucagon-like peptide 1 receptor agonists in management of obesity Diana Isaacs, Pharm.D., BCPS, BC-ADM, CDE, Chicago State University, Chicago, IL, and Oak Lawn VA Clinic of Edward Hines Jr. VA

More information

DEKALB WOMEN S SPECIALISTS 5295 HWY 78 STE. N STONE MOUNTAIN, GA

DEKALB WOMEN S SPECIALISTS 5295 HWY 78 STE. N STONE MOUNTAIN, GA DEKALB WOMEN S SPECIALISTS 5295 HWY 78 STE. N STONE MOUNTAIN, GA.30087 404-508-2000 WWW.DEKALBWOMEN.COM * PATIENT INFORMATION FORM FOR WEIGHT LOSS * TODAY S DATE: PATIENTS NAME: STREET ADDRESS: CITY /

More information

Specific treatment for obesity will be determined by your health care provider based on:

Specific treatment for obesity will be determined by your health care provider based on: Regardless of the type or combination of obesity treatment, goal setting is an important part of any obesity treatment plan. While a person may want to lose a large amount of weight because of societal

More information

The ABCDs of Obesity

The ABCDs of Obesity The ABCDs of Obesity Adipose Based Chronic Disease Michael A. Bush, M.D. Clinical Chief, Division of Endocrinology Cedars-Sinai Medical Center Clinical Associate Professor, Geffen School of Medicine, UCLA

More information

Tackling Obesity with Sensitive, Tailored Conversation Foundation. Prepared for: California Nurse Practitioner Conference March 23, 2014

Tackling Obesity with Sensitive, Tailored Conversation Foundation. Prepared for: California Nurse Practitioner Conference March 23, 2014 Tackling Obesity with Sensitive, Tailored Conversation Foundation Prepared for: California Nurse Practitioner Conference March 23, 2014 Course Objectives 1 2 3 4 List examples of NP- Implemented successful

More information

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Before using medications to transition and feminize, you need to know the possible advantages, disadvantages and risks

More information

Obesity the global epidemic

Obesity the global epidemic Obesity the global epidemic Obesity the global epidemic 35% 35% 35% 34% 34% 33% 33% 33% 32% 43% Top 10 obese countries Smoking Obesity Alcohol Inf. Diseases Toxins Vehicle Collisions Firearms Death Sexual

More information

Please complete and return this form to be considered for evaluation

Please complete and return this form to be considered for evaluation Office use only: MRN BMI Please complete and return this form to be considered for evaluation Name Date Age Date of Birth / / Sex M F Address City State Zip code Preferred Daytime Phone: ( ) - Do you have

More information

Welcome to our Center! We are so glad you have chosen our center to assist you with your weight loss goals!

Welcome to our Center! We are so glad you have chosen our center to assist you with your weight loss goals! Welcome to our Center! We are so glad you have chosen our center to assist you with your weight loss goals! What to expect.. Your first appointment with our center will last approximately one hour, possibly

More information

The TRUE Guide to Diabetes Care

The TRUE Guide to Diabetes Care monitor track manage A TRUEinsight Guide manage The TRUE Guide to Diabetes Care Important Questions and Informative Answers for People With Diabetes A Guide to Diabetes Care You ve been diagnosed with

More information

Should I Stand Watch?

Should I Stand Watch? Should I Stand Watch? A Review of New Medications and Herbal Products and the Possible Effects on Licensed Operators Michael L. Zaruba, M.D. Auburn Family Health Center NPPD/Cooper Nuclear Station Objectives

More information

The Treatment of Obesity: Diet and Medication

The Treatment of Obesity: Diet and Medication The Treatment of Obesity: Diet and Medication Doina Kulick, M.D., M.S., F.A.C.P. Associate Professor of Medicine University of Nevada Reno School of Medicine Financial Disclosure: None 2013 Washoe County

More information

How to End the Obesity and Diabetes Crisis in America and the World

How to End the Obesity and Diabetes Crisis in America and the World How to End the Obesity and Diabetes Crisis in America and the World David S. Weed, Psy.D. Partners for a Healthier Community, Inc. Childhood Obesity Rates Rising There is no evidence of a decrease in the

More information

Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University

Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University Objectives Discuss the evolution of obesity as a diagnosis and disease.

More information

Disclosures. Objectives. Impact of Obesity in Primary Care Practice and What To Do About It. Intuitive Surgical. Consultant

Disclosures. Objectives. Impact of Obesity in Primary Care Practice and What To Do About It. Intuitive Surgical. Consultant Disclosures Intuitive Surgical Consultant Stephen Archer, MD, FACS, FASMBS Director, Bariatric Surgery, St. Charles Medical Center Bend, OR Grand Rounds June 15, 2018 2 Objectives Impact of Obesity in

More information